TheraRadar
Data updated: May 26, 2026

DETECTNET (copper cu-64 dotatate)

Positron Emitting Activity
Orphan Drug Priority Review Fast Track
Oncology Approved 2020-09-03

Detectnet is a radioactive diagnostic tool used to help locate neuroendocrine tumors in adult patients. When used alongside positron emission tomography (PET) scans, it helps identify specific tumors that express somatostatin receptors. This imaging agent allows healthcare providers to visualize the presence and position of these malignant cells throughout the body.

Source: FDA Label • CURIUM • Radioactive Diagnostic Agent

How DETECTNET Works

This agent works by binding to somatostatin receptors, specifically targeting the subtype 2 receptors that are often overexpressed on malignant neuroendocrine cells. Once attached to these cells, the radioactive copper component emits positrons. This emission allows the tumors to be detected and localized using PET imaging technology.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
5
Years on Market

Details

Status
Prescription
First Approved
2020-09-03
Patent Cliff
2041

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: COPPER CU-64 DOTATATE

DETECTNET Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2020 to 2021
Dec 2021 SUPPL
Label · Labeling
Sep 2020 ORIGINAL Priority
New Drug · Type 1 - New Molecular Entity

What DETECTNET Treats

1 indications

DETECTNET is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Neuroendocrine Tumors
Source: FDA Label

DETECTNET Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Direct competitors

2

Same target(s) AND same indication — head-to-head.

MoA expansion candidates

2

Same target(s), different indications — where else is this mechanism being explored?

Unlock 5 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DETECTNET

3 of 4

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AFINITOR
EVEROLIMUS
1 shared
Novartis
Shared indications:
Neuroendocrine Tumors
AFINITOR DISPERZ
EVEROLIMUS
1 shared
Novartis
Shared indications:
Neuroendocrine Tumors
NETSPOT
GALLIUM DOTATATE GA-68
1 shared
AAA USA INC
Shared indications:
Neuroendocrine Tumors
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DETECTNET FDA Label Details

Indications & Usage

FDA Label (PDF)

DETECTNET is indicated for the treatment of Neuroendocrine Tumors.

View full patent landscape →
4 OB patents · 2 families · 33 international docs across 13 countries

DETECTNET Patents & Exclusivity

Latest Patent: Sep 2041
Exclusivity: Sep 2027

Patents (4 active)

US12102696 Expires Sep 3, 2041
US10383961 Expires Jul 2, 2033
US10159759 Expires Aug 23, 2032
US11160888 Expires Aug 23, 2032

Exclusivity

ODE-317 Until Sep 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for DETECTNET

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2041
  • 4 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 4 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.